Hadrien is a Partner at Kurma Partners who has participated in a dozen investments of the Kurma Biofund II and III funds. Hadrien has actively contributed to the creation of several portfolio companies such as Corlieve Therapeutics (sold to uniQure), Emergence Therapeutics (sold to Lilly), Imcheck Therapeutics, Flamingo Therapeutics as well as Ermium Therapeutics where he serves as Board member. Hadrien holds a PharmD from the Faculty of Pharmacy, Lille, and a MSc in Entrepreneurship from the ESSEC Business School.